Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Deuterated psilocybin - Lennham Pharmaceuticals

X
Drug Profile

Deuterated psilocybin - Lennham Pharmaceuticals

Alternative Names: D-Psilocybin - Lennham Pharmaceuticals; Psilocybin - Lennham Pharmaceuticals

Latest Information Update: 02 Jun 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Lennham Pharmaceuticals
  • Class Analgesics; Anti-infectives; Anti-inflammatories; Antidepressants; Antineoplastics; Antipsychotics; Anxiolytics; Behavioural disorder therapies; Dimethylamines; Drug withdrawal therapies; Indoles; Mood stabilisers; Neuropsychotherapeutics; Organophosphorus compounds; Phytotherapies; Small molecules
  • Mechanism of Action ATP-binding cassette transporter modulators; Serotonin 5-HT2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Major depressive disorder; Post-traumatic stress disorders

Most Recent Events

  • 31 May 2022 Lennham Pharmaceuticals has patent protection for methods of using psilocybin and psilocin in an MAO-A deficient patient population in USA
  • 12 Sep 2021 Lennham Pharmaceuticals has patents pending for methods of using psilocybin and psilocin in USA
  • 01 Sep 2021 Deuterated psilocybin is available for licensing as of 01 Sep 2021. https://www.lennham.com/

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top